Stempoint Capital’s Repligen RGEN Stock Holding History

Stempoint Capital’s Portfolio RGEN Stock Details RGEN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-15,707	Closed	-$2.57M	–	111
2025 Q4	$2.57M	Buy	+15,707	New	+$2.46M	0.44%	50

Other funds holding RGEN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

UCFA

United Capital Financial Advisors Irving, Texas $16.3B AUM 16.34% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Stempoint Capital's RGEN Position: Q1 2026 in Review

Stempoint Capital sold out of Repligen (RGEN) in Q1 2026, closing a stake of 15,707 shares — an estimated $2.57M sold.

Stempoint Capital first reported a position in RGEN in Q4 2025 and held it in 1 quarter. The position peaked at $2.57M in Q4 2025. 441 funds tracked by Wall St. Rank hold RGEN as of Q1 2026.

Stempoint Capital reported no remaining Repligen position as of Q1 2026 after selling out during the quarter.
Stempoint Capital sold 15,707 Repligen shares in Q1 2026, an estimated $2.57M.
Stempoint Capital first reported a position in Repligen in Q4 2025 and held it in 1 quarter.
Stempoint Capital's Repligen position peaked at $2.57M in Q4 2025.
441 funds tracked by Wall St. Rank held Repligen as of Q1 2026.

Based on Stempoint Capital's 13F filing for Q1 2026, filed 15 May 2026.